NCT01081652View on ClinicalTrials.gov

A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)

PHASE3CompletedINTERVENTIONAL

Enrollment

238

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

May 31, 2005

Conditions

Infertility

Interventions

DRUG

Micronised Progesterone

Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.

DRUG

Progesterone

Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.

Trial Locations (1)

100191

Peking University 3rd Hopistal, Beijing

All Listed Sponsors

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01081652 - A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET) | Biotech Hunter | Biotech Hunter